Dr. Geoffrey Oxnard: Are Patients or Payers Objecting to Repeat Biopsy?
Dr. Geoffrey Oxnard, Dana Farber Cancer Institute, discusses the issue of patients or payers objecting to repeat biopsies.
Apr 12, 2013•1 min
GRACEcast Lung Cancer Video
Oncology experts summarize current and emerging issues in cancer management for patients and caregivers. Information from the Global Resource for Advancing Cancer Education (GRACE) helps people to become informed partners in their care.
Last refreshed: ⓘ
Follow this podcast in the Metacast mobile app to refresh it and see new episodes.
Podcasts are better in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episodes
Dr. Greg Riely on Muliplex Next Generation Sequencing and its Effect on Molecular Oncology Practice
Dr. Greg Riely, from Memorial Sloan-Kettering, discusses the concept of multiplex next generation sequencing and how it could change molecular oncology.
Apr 11, 2013•4 min
Dr. Phil Bonomi on the Most Promising Upcoming New Targeted Agents and Molecular Pathways for Lung Cancer Treatment
Dr. Phil Bonomi, from Rush University, provides his view on the targeted therapy approaches most likely to become clinically useful in lung cancer over the next several years.
Apr 11, 2013•2 min
Dr. Karen Kelly on "My Approach to Maintenance Therapy for Advanced NSCLC"
Dr. Karen Kelly of the University of California, Davis, discusses the evidence and her personal interpretation and recommended approach to maintenance therapy for advanced non-small cell lung cancer.
Apr 10, 2013•2 min
Dr. David Spigel on the Utility of Molecular Marker Results in the Adjuvant Setting for Early Stage Non-Small Cell Lung Cancer
Dr. David Spigel addresses the question of whether to obtain molecular marker results in patients with early stage lung cancer and what to do with that information if it is available for potential application in the adjuvant setting.
Apr 10, 2013•2 min
Dr. Sarah Goldberg: Recommending a Repeat Biopsy with Acquired Resistance to a Targeted Therapy
Dr. Sarah Goldberg, Yale Cancer Center, reviews her thought process in recommending a repeat biopsy at initial diagnosis or after progression for patients with advanced lung cancer.
Apr 08, 2013•2 min
Drs. Ross Camidge and Corey Langer: Will Our Gains in Targeted Therapies Be Generalizable to a Wider Range of Lung Cancers?
Drs. Ross Camidge and Corey Langer provide their perspective on the likelihood that molecular oncology principles and targeted therapies will become more broadly applicable for patients with squamous and other lung cancer subtypes.
Apr 08, 2013•2 min
Highlights in Lung Cancer, 2013, Part 5: Maintenance Therapy in Advanced NSCLC (video)
Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, summarizes evidence from the PARAMOUNT trial, demonstrating a survival benefit for continuation maintenance therapy with Alimta (Pemetrexed) in advanced non-small cell lung cancer.
Apr 07, 2013•4 min
Dr. Lecia Sequist: Will New Forms of Mutation Testing Become Available Beyond the Major Research Centers?
Dr. Lecia Sequist of Massachusetts General Hospital gives her view on more widespread availability of new mutation tests
Apr 05, 2013•2 min
Dr. Heather Wakelee: How Should We Manage Acquired Resistance with a Single Lesion or More Diffuse Progression?
Dr. Heather Wakelee from Stanford University offers her insights on how to approach a patient with gradual progression in a single site, especially in the brain, or more multifocal progression after a good initial response to a targeted agent for lung cancer.
Apr 05, 2013•54 sec
Dr. Ravi Salgia: How Do I Discuss the Side Effects of Targeted Therapies, as Compared with Chemotherapy?
Dr. Ravi Salgia from University of Chicago discusses his perspective on side effects of targeted therapies as compared with standard chemotherapy for patients with lung cancer.
Apr 03, 2013•1 min
Dr. Karen Reckamp on "Which patients do you send molecular marker testing for, and what tests do you seek?"
Dr. Karen Reckamp from City of Hope Cancer Center in Duarte, CA describes which patients with advanced NSCLC she seeks molecular marker testing on, and the particular markers she prioritizes.
Apr 03, 2013•1 min
Dr. Greg Riely on "I just found out I have an EGFR mutation, and I'm in the middle of chemo. What now?"
Dr. Greg Riely offers his view on the best way to approach the common scenario of an EGFR mutation or other "driver mutation" being identified after a patient is already on first line chemotherapy. When should we switch from one treatment to another?
Mar 31, 2013•1 min
Dr. Geoffrey Oxnard on What Molecular Markers to Test for in Advanced NSCLC, and in Whom?
Dr. Oxnard from Dana Farber Cancer Institute provides his insight on which patients with advanced non-small cell lung cancer he pursues molecular testing for, and which molecular markers are the highest priority.
Mar 31, 2013•3 min
Highlights in Lung Cancer, 2013, Part 4: Squamous Cell NSCLC and antiPD1 Immunotherapy (video)
Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, describes new targets for squamous cell non-small cell lung cancer and anti-PD1 immunotherapy that has emerged as one of the most promising new developments in lung cancer from 2012.
Mar 30, 2013•8 min
Highlights in Lung Cancer, 2013: MEK Inhibitors for KRAS Mutation-Positive NSCLC (video)
Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, reviews exciting new data illustrating the potential benefits of the MEK inhibitor selumetinib in treating KRAS mutation-positive advanced non-small cell lung cancer.
Mar 29, 2013•5 min
Dr. Sarah Goldberg on the Utility of Molecular Marker Results in the Adjuvant Setting for Early Stage Non-Small Cell Lung Cancer
Dr. Sarah Goldberg addresses the question of whether to obtain molecular marker results in patients with early stage lung cancer and what to do with that information if it is available for potential application in the adjuvant setting.
Mar 29, 2013•1 min
Dr. Lecia Sequist on Relevant Emerging Molecular Targets in Lung Cancer
Dr. Lecia Sequist of Massachusetts General Hospital describes the new targets she envisions as relevant for effective treatments in lung cancer over the next several years.
Mar 29, 2013•1 min
Dr. Heather Wakelee on the Most Promising New Agents and Pathways for Treating Lung Cancer in the Coming Years
Dr. Heather Wakelee from Stanford University presents her view on the most promising emerging targeted therapies and pathways for treating lung cancer in the coming years.
Mar 25, 2013•2 min
Drs. Ross Camidge and Corey Langer: How Should We Manage Acquired Resistance with a Single Lesion or More Diffuse Progression?
Drs. Ross Camidge and Corey Langer offer their insights on how to approach a patient with gradual progression in a single site, especially in the brain, or more multifocal progression after a good initial response to a targeted agent for lung cancer.
Mar 25, 2013•4 min
Dr. David Spigel: We've Probably Made Maintenance Therapy More Complicated Than It Needs To Be
Dr. David Spigel from Sarah Cannon Cancer Center in Nashville, TN, discusses the evidence and his personal interpretation and recommended approach to maintenance therapy for advanced non-small cell lung cancer.
Mar 25, 2013•3 min
Highlights in Lung Cancer, 2012: ALK Inhibitors for Patients with ALK or ROS1 Gene Rearrangements (video)
Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, describes emerging data on the efficacy of ALK inhibitors for patients with advanced NSCLC that harbors an ALK or ROS1 rearrangement.
Mar 23, 2013•11 min
Dr. Alan Sandler: My Approach to Acquired Resistance for Targeted Therapies in Lung Cancer
Dr. Alan Sandler from OHSU describes how acquired resistance to targeted therapies in lung cancer is similar to what is seen with chemo and comments on how he manages patients demonstrating gradual acquired resistance in advanced lung cancer.
Mar 21, 2013•2 min
Dr. Greg Riely on the Most Promising Upcoming New Targeted Agents and Molecular Pathways for Lung Cancer Treatment
Dr. Greg Riely, Memorial Sloan-Kettering, provides his view on the targeted therapy approaches most likely to become clinically useful in lung cancer over the next several years.
Mar 21, 2013•2 min
Dr. Ravi Salgia on "My Approach to Maintenance Therapy for Advanced NSCLC"
Dr. Ravi Salgia from University of Chicago provides his general strategy for patients with advanced non-small cell lung cancer who are candidates for maintenance therapy after first line treatment.
Mar 20, 2013•2 min
Dr. William Pao on "How Concerned Should We Be About Different Testing Methods, as well as the Heterogeneity of Different Biopsy Results from the Same Patient?"
Dr. William Pao explains the caveats of molecular testing in terms of differences in testing methods through different laboratories and the heterogeneity of molecular findings in different biopsies even within the same individual with lung cancer.
Mar 20, 2013•2 min
Highlights in Lung Cancer, 2012: New Options for EGFR Mutation-Positive NSCLC (video)
Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, reviews new data supporting new treatment options for EGFR mutation-positive patients with advanced NSCLC being newly treated or developing acquired resistance to prior EGFR inhibitors.
Mar 18, 2013•19 min
Dr. Geoffrey Oxnard on Translating the Benefits of Molecular Oncology More Broadly: The Tissue is the Issue
Dr. Geoffrey Oxnard conveys a central theme that the benefits of molecular oncology and optimal application of targeted therapies are dependent on a change in collecting tissue that works to obtain far more tissue than was historically required.
Mar 14, 2013•2 min
Dr. Heather Wakelee: My Approach to Repeat Biopsies For Advanced NSCLC Patients Who Have Insufficient Tissue for Molecular Testing
Dr. Heather Wakelee from Stanford University expresses her practice pattern for patients with advanced non-small cell lung cancer who would need a repeat biopsy to obtain sufficient tissue to perform molecular marker testing.
Mar 14, 2013•1 min
Dr. Karen Reckamp: Will Our Gains in Targeted Therapies Be Generalizable to a Wider Range of Lung Cancers?
Dr. Karen Reckamp, City of Hope Cancer Center, provides her perspective on the likelihood that molecular oncology principles and targeted therapies will become more broadly applicable for patients with squamous and other lung cancer subtypes.
Mar 13, 2013•1 min
For the best experience, listen in Metacast app for iOS or Android